LifeMD Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-39785 LIFEMD, INC.(Exact name of registrant as specified in its charter) (866) 351-5907(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $.01 per share8.875% Series A Cumulative Perpetual PreferredStock, par value $0.0001 per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallreporting company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 5, 2026, there were 48,362,510 shares of the registrant’s common stock outstanding. LIFEMD, INC.FORM 10-QFOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 TABLE OF CONTENTS PagePART I. FINANCIAL INFORMATION3ITEM 1.Financial Statements (unaudited)3Consolidated Balance Sheets3Consolidated Statements of Operations4Consolidated Statements of Stockholders’ Equity (Deficit)5Consolidated Statements of Cash Flows6Notes to Consolidated Financial Statements7ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations26ITEM 3.Quantitative and Qualitative Disclosures about Market Risk34ITEM 4.Controls and Procedures35PART II. OTHER INFORMATION37ITEM 1.Legal Proceedings37ITEM 1A.Risk Factors37ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds37ITEM 3.Defaults Upon Senior Securities37ITEM 4.Mine Safety Disclosures37ITEM 5.Other Information37ITEM 6.Exhibits38SIGNATURES392 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS LIFEMD, INC.CONSOLIDATED BALANCE SHEETS(Unaudited) LIFEMD, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) The accompanying notes are an integral part of these unaudited consolidated financial statements. LIFEMD, INC.NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS Nature of Business LifeMD,Inc.is a patient-centric,direct-to-patient healthcare company providing a high-quality,cost-effective,andconvenient way for patients to access virtual medical care and pharmacy services. Through the Company’s vertically integrated caremodel, it combines proprietary technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (“AI”)-enabled operational systems to deliver longitudinal care at scale. The Company’s mission is to empower individuals to live healthierlives by expanding access to high-quality virtual and in-home healthcare services. The Company’s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescriptionmedications, often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (“OTC”) products. All products are available on a subscription or membership basis, where a patient can subscribe to receiveregular shipments of prescribed medications or products. This creates convenience and often discounted pricing opportunities forpatients and recurring revenue streams for the Company. With its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair lossincluding Food and Drug Administration (“FDA”) approved OTC minoxidil and an FDA-cleared medical device and a personalizedtelehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a fullline of oral and topical prescription medications for h